Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jan 18;15(1):2360.
doi: 10.1038/s41598-025-86566-y.

Oxytocin levels in response to CRH administration in hypopituitarism and hypothalamic damage: a randomized, crossover, placebo-controlled trial

Queralt Asla  1   2 , Maite Garrido  3 , Eulàlia Urgell  4 , Sílvia Terzan  4 , Alicia Santos  1   5 , Mercè Fernández  6 , Nimmy Varghese  7   8 , Cihan Atila  9   10 , Anna Calabrese  11 , Betina Biagetti  12   13 , Franziska Plessow  14   15 , Ignasi Gich  16   17 , Mirjam Christ-Crain  9   10 , Anne Eckert  7   8 , Susan M Webb  5   13 , Elizabeth A Lawson  14   15 , Anna Aulinas  18   19
Affiliations
Randomized Controlled Trial

Oxytocin levels in response to CRH administration in hypopituitarism and hypothalamic damage: a randomized, crossover, placebo-controlled trial

Queralt Asla et al. Sci Rep. .

Abstract

Increasing evidence supports the presence of oxytocin deficiency (OXT-D) in patients with hypopituitarism and hypothalamic damage (HHD), that might be associated with neuropsychological deficits and sexual dysfunction, leading to worse quality of life (QoL). Therefore, identifying a provocative test to diagnose an OXT-D will be important. Corticotropin-releasing hormone (CRH) is a candidate for such a test as it increases oxytocin secretion in animal models. This study aimed to examine the effects of CRH on oxytocin release in HHD compared to healthy controls (HC) and to describe the psychopathology, sexual function and QoL and their associations with oxytocin. This is a single-blind, randomized, placebo-controlled, proof-of-concept study (NCT04902235) with crossover assignment (CRH vs. placebo). Nineteen HHD patients (10 females) and 20 HC (11 females) completed two visits, receiving CRH or placebo in random order and completed validated questionnaires to assess psychopathology, sexual function and QoL. Samples were collected over 120 min to assess oxytocin. Linear mixed-effects regression model evaluated the change in oxytocin after CRH/placebo in HHD vs. HC. CRH administration did not impact oxytocin concentrations across groups over time (p = 0.97). HHD had greater psychopathology (most ps < 0.05), sexual dysfunction (p < 0.03) and worse QoL (p < 0.001) compared to HC, nevertheless, baseline oxytocin concentrations and area under the curve of oxytocin were not significantly associated with psychopathology, sexual function or QoL, neither in HHD or HC. In conclusion, CRH administration does not appear to be a suitable provocative test for diagnosing OXT-D in HHD. Identifying a reliable diagnostic test for OXT-D remains crucial. Alternative provocative tests or biomarkers should be explored.

Keywords: Arginine-vasopressin deficiency; Corticotropin-releasing hormone; Hypopituitarism; Hypothalamic damage; Oxytocin; Pituitary disease.

PubMed Disclaimer

Conflict of interest statement

Declaration. Competing interests: EAL receives grant support and research study drug from Tonix Pharmaceuticals and receives royalties from UpToDate. EAL and/or immediate family member holds stock in Thermo Fisher Scientific, Zoetis, Danaher Corporation, Intuitive Surgical. EAL is an inventor on US provisional patent application no. 63/467,980 (Oxytocin-based therapeutics to improve cognitive control in individuals with attention deficit hyperactivity disorder). No other conflicts of interest, financial or otherwise, are declared by the authors.

Figures

Fig. 1
Fig. 1
Scheme of main study visits and procedures. HC, healthy controls; HHD, patients with hypopituitarism and hypothalamic damage, CRH corticotropin-releasing hormone; T, timepoint.
Fig. 2
Fig. 2
Study flow diagram. HC, healthy controls; HHD, patients with hypopituitarism and hypothalamic damage, CRH corticotropin-releasing hormone; V1, visit 1 and V2; visit 2.
Fig. 3
Fig. 3
Response of OXT concentrations over time (from T0 to T120) after CRH across groups (HHD vs. HC) expressed as mean and standard error of the mean. OXT, oxytocin; T; timepoint; HC, healthy controls; HHD, patients with hypopituitarism and hypothalamic damage, CRH corticotropin-releasing hormone.
See this image and copyright information in PMC

References

    1. Lynch, S. et al. Psychiatric morbidity in adults with hypopituitarism. J. R. Soc. Med.87, 445–447. 10.1177/014107689408700805 (1994). - DOI - PMC - PubMed
    1. Fleseriu, M. et al. Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab.101, 3888–3921. 10.1210/jc.2016-2118 (2016). - DOI - PubMed
    1. Andela, C. D., Scharloo, M., Pereira, A. M., Kaptein, A. A. & Biermasz, N. R. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary18, 752–776. 10.1007/s11102-015-0636-7 (2015). - DOI - PubMed
    1. Bulow, B., Hagmar, L., Orbaek, P., Osterberg, K. & Erfurth, E. M. High incidence of mental disorders, reduced mental well-being and cognitive function in hypopituitary women with GH deficiency treated for pituitary disease. Clin. Endocrinol. (Oxf)56, 183–193 (2002). - DOI - PubMed
    1. Vila, G. & Fleseriu, M. Fertility and pregnancy in women with hypopituitarism: A systematic literature review. J. Clin. Endocrinol. Metab.10.1210/clinem/dgz112 (2020). - DOI - PubMed

Publication types

Associated data

LinkOut - more resources